January 9, 2023
Read in 2 minutes
Source/Disclosure
Disclosure:
Bayer endorsed this study. Osman does not report related financial disclosures. Eckhart has received funding from Bayer, Apnimed, Invicta He Medical, Takeda Pharmaceuticals, and a Collaborative Research Center (CRC-P) consortium grant between the Australian government, academia and industry (industry partner: Oventus Medical). I am reporting that I have received it. He has also served as a consultant to Bayer and Takeda Pharmaceuticals and serves on the Scientific Advisory Boards of Agnimed and Invicta Medical. See research for relevant financial disclosures of all other authors.
According to a study published in , drugs administered via nasal spray may be an alternative treatment option for patients with obstructive sleep apnea by improving upper airway collapsibility. chest.
This is the first time that this drug, a novel and potent TWIK-related acid-sensitive K+ (TASK) 1/3 channel antagonist, has been studied in humans.
In addition, the researchers found that all tested applications and doses of BAY2586116 lowered and improved critical closure pressure in patients. Source: Adobe Stock
“Although it is a small study, our findings represent the first detailed investigation of this new treatment in patients with OSA, and the results are encouraging.” Dr. Amal M. Osman FHMRI: Sleep Health from the Sleep Institute at Flinders University said in a press release. “The drug we tested was designed to target specific receptors expressed on the surface of the upper airway, making it easier to engage surrounding muscles to keep the airway open during sleep. Although there is still a long way to go in terms of clinical trials and development, our research suggests that targeting these receptors may be a promising avenue for future treatments. is shown.
In a double-blind, randomized crossover study, Osman and colleagues found that BAY2586116 (Bayer), a TASK 1/3 K+ channel antagonist, helps keep airways open during sleep.
In two overnight physiological studies, researchers randomized patients to receive either 160 µg of BAY2586116 or a placebo nasal spray. After her two nights, participants could also participate in three more overnight studies. All received her BAY2586116 in this study, but BAY2586116 nasal drops (n = 10), half-dose nasal drops (n = 10) or direct application using an endoscope (n = 8).
A variety of tools, including a polysomnography device, epiglottis compression catheter, pneumotachograph, and nasal mask, were used to track patients’ sleep and breathing patterns during drug administration.
When measuring the upper airway critical closure pressure during sleep, researchers found a mean value of 2.1 ± 1.8 cmH.2O (range, –0.16 to 5 cmH2O) Among patients who received placebo nasal spray. However, BAY2586116 spray lowered the critical closing pressure of the upper airway to 0.1 ± 4.4 cmH.2O (range, –5.7 to 9.7 cmH2O).
In addition, the researchers found that all tested applications and doses of BAY2586116 reduced and improved the patient’s critical closure pressure with a nasal depression of 0.9 ± 2.6 cmH.2O, half spray at 0 ± 2.2 cmH2O at 0.4 ± 3.3 cmH and endoscopic applications2O.
Approximately 60% of patients had >2 cmH,2Although there was a 0% improvement with the nasal spray method compared to only 20% of patients using the nasal spray method, mixed model results showed no systemic differences between different application methods and dosages. was not shown.
When transiently reduced to atmospheric pressure on CPAP, 82% of 11 patients had no flow in breaths 3-5 during treatment with placebo, whereas BAY2586116 high-dose spray and endoscope increased the mean peak inspiratory flow response.
“At this time, there are no approved treatments for OSA.” Danny J. eckert, doctorate, The director of Flinders Sleep Institute FHMRI: Sleep Health said in a release: “But the prospect of effective new drugs grows stronger each year as our understanding of the various reasons people become her OSA grows.”
